| |||||||||
| These apoB38.9 mutant mice may be useful to study the genetic and molecular mechanism of apoB defects and lipid metabolism/liver fat accumulation, the relationship between hepatic steatosis and insulin resistance, the progression of advanced non-alcoholic fatty liver diseases (NAFLD), and atherosclerosis. In addition, all three congenic apoB38.9 strains (Stock No. 007679, Stock No. 007682, and Stock No. 007683) may be useful in conjunction with other apoB mutant mice, including Stock No. 002053 (apoB70), Stock No. 002876 (apoB48-only), and Stock No. 002877 (apoB100-only). | |||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered Mutant Mice. Mating System +/+ sibling x Heterozygote (Female x Male) Species laboratory mouse Generation N9+ (14-MAR-08) Donating Investigator Gustav Schonfeld, Washington University School of Medicine Description
Mice homozygous for this apoB38.9 allele (apoB38.9/38.9) are viable with impaired fertility, bearing a premature stop codon at residue 1767 of the targeted gene. As a result, homozygous plasma shows a truncated apoB38.9 as the sole apoB protein. Plasma from heterozygous (apoB+/38.9) mice have reduced apoB100 and apoB48 compared to wildtype, with apoB38.9 representing 20% of total circulating apoB. This apoB38.9 truncation affects both apoB100 and apoB48 metabolism in mice, and mimics human Familial Hypobetalipoproteinemia (FHBL). Homozygous and, to a lesser extent, heterozygous mice exhibit symptoms of FHBL due to impaired lipoprotein export system/VLDL secretion, including elevated hepatic triglyceride (TG), cholesterol and free fatty acids (FFA), with decreased plasma TG and cholesterol. Because plasma and liver lipid profiles range from mild to severe in populations of heterozygous apoB38.9 mice on a mixed (C57BL/6J;129X1/SvJ) genetic background, apoB+/38.9 congenic mice were generated on three different inbred strains with characterized differences in liver fat: SWR/J (low liver TG strain, ~40mg/dL), C57BL/6J (medium liver TG, ~140mg/dL), and BALB/cByJ (high liver TG strain, ~200 mg/dL). All three apoB+/38.9 congenic strains exhibit significantly impaired hepatic TG secretion compared to their respective genetic backgrounds, with significant interactions observed between genetic background and apoB genotype for liver TG and FFA. BALB/cByJ-apoB38.9 mice (Stock No. 007683) exhibit the greatest hepatic TG and FFA increase (probably due to elevated hepatic TG synthesis rate). Despite having the lowest degree of hepatic steatosis among the three apoB+/38.9 congenic strains, SWR/J-apoB38.9 mice (Stock No. 007679) show insulin resistance, with BALB/cByJ-apoB38.9 mice exhibiting intermediate and C57BL/6J-apoB38.9 mice (Stock No. 007682) exhibiting the greatest insulin resistance. Additional comparisons between the three congenic strains reveal that C57BL/6J-apoB38.9 mice have significant increase of fatty acid synthesis rate compared to the other two congenic strains, while SWR/J-apoB38.9 mice show dynamic feedback regulation of fatty acids and TG synthesis and beta-oxidation in response to excessive hepatic TG accumulation. Gender dimorphism is observed; while BALB/cByJ-apoB38.9 males have reduced plasma cholesterol levels compared to wildtype males, females from all three apoB+/38.9 congenic strains have reduced plasma cholesterol compared to wildtype females. Male BALB/cByJ-apoB38.9 and C57BL/6J-apoB38.9 mice have significant reduction of liver TG synthesis compared to wildtype males, while SWR/J-apoB38.9 females show the same significant reduction. These apoB38.9 mutant mice may be useful to study the genetic and molecular mechanism of apoB defects and lipid metabolism/liver fat accumulation, the relationship between hepatic steatosis and insulin resistance, the progression of advanced non-alcoholic fatty liver diseases (NAFLD), and atherosclerosis. These apoB38.9 mutant mice may also be useful in conjunction with other apoB mutant mice, including Stock No. 002053 (apoB70), Stock No. 002876 (apoB48-only), and Stock No. 002877 (apoB100-only).Development
A targeting vector was designed (by site-directed mutagenesis) to delete nucleotide 5449 of the mouse apo B cDNA sequence (the deletion is predicted to produce a premature stop codon at the same position (i.e. residue 1767) as that occurring in the apo B-38.9 mutation of human familial hypobetalipoproteinemia (FHBL) subjects). This also inserted a loxP-flanked PGK-neo cassette within intron 24. The construct was electroporated into 129X1/SvJ-derived RW4 embryonic stem (ES) cells. Correctly targeted ES cells were transiently transfected with a cre-expressing vector to remove the selection cassette (leaving a single loxP site in intron 24) and then injected into C57BL/6 blastocysts. The resulting chimeric males were bred to C57BL/6 females. Heterozygotes were then backcrossed to C57BL/6J inbred mice (see Stock No. 000664) for 8 generations prior to arrival at The Jackson Laboratory.
Control Information
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Apobtm1.1Zc allele
007683 CByJ.129X1(Cg)-Apobtm1.1Zc/J 007679 SWR.129X1(B6)-Apobtm1.1Zc/J View Strains carrying Apobtm1.1Zc (2 strains)
002053 B6.129P2-Apobtm1Unc/J 002878 B6;129-Apobtm1Sgy Apoetm1Unc/J 002879 B6;129-Apobtm2Sgy Apoetm1Unc/J 002876 B6;129S-Apobtm1Sgy/J 003000 B6;129S-Apobtm2Sgy Ldlrtm1Her/J 002877 B6;129S7-Apobtm2Sgy/J 004192 STOCK Mttptm2Sgy Ldlrtm1Her Apobtm2Sgy Tg(Mx1-cre)1Cgn/J
Additional Web Information
Congenic Nomenclature
Phenotype
Phenotype Information
Apolipoprotein B; APOB - Models with phenotypic similarity to human disease where etiologies involve orthologs.1
1 Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Apobtm1.1Zc/Apob+
involves: 129X1/SvJ * C57BL/6
- homeostasis/metabolism phenotype
- decreased circulating LDL cholesterol level (MGI Ref ID J:65191)
- decreased circulating VLDL cholesterol level (MGI Ref ID J:65191)
- liver/biliary system phenotype
- hepatic steatosis (MGI Ref ID J:65191)
Apobtm1.1Zc/Apobtm1.1Zc
involves: 129X1/SvJ * C57BL/6
- lethality-prenatal/perinatal
- prenatal lethality (MGI Ref ID J:65191)
- fewer than expected numbers of offspring born from heterozygous matings
- homeostasis/metabolism phenotype
- decreased circulating HDL cholesterol level (MGI Ref ID J:65191)
- decreased circulating LDL cholesterol level (MGI Ref ID J:65191)
- decreased circulating VLDL cholesterol level (MGI Ref ID J:65191)
- decreased circulating triglyceride level (MGI Ref ID J:65191)
- liver/biliary system phenotype
- hepatic steatosis (MGI Ref ID J:65191)
This mouse can be used to support research in many areas including:
Cardiovascular Research
Atherosclerosis
Hypercholesterolemia
Hypertriglyceridemia
Hypocholesterolemia
Hypotriglyceridemia
Other (altered fat metabolism)
Other (altered lipoprotein profile)
Diabetes and Obesity Research
Insulin Resistance
Internal/Organ Research
Liver Defects
Metabolism Research
Lipid Metabolism
Mouse/Human Gene Homologs
hypobetalipoproteinemia, familial
Reproductive Biology Research
Fertility Defects
Research Tools
Cardiovascular Research
Diabetes and Obesity Research
Internal/Organ Research
Metabolism Research
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Apobtm1.1Zc | ||
|---|---|---|---|
| Allele Name | targeted mutation 1.1, Zhouji Chen | ||
| Allele Type | Targeted (knock-in) | ||
| Common Name(s) | apoB38.9; | ||
| Mutation Made By | Zhouji Chen, Washington University School of Medicine | ||
| Strain of Origin | 129X1/SvJ | ||
| ES Cell Line Name | RW-4 | ||
| ES Cell Line Strain | 129X1/SvJ | ||
| Gene Symbol and Name | Apob, apolipoprotein B | ||
| Chromosome | 12 | ||
| Gene Common Name(s) | AI315052; Aa1064; Ac1-060; ApoB-100; ApoB-48; FLDB; expressed sequence AI315052; | ||
| Molecular Note | Deletion of nucleotide 5449 in exon 26 and a loxP-flanked PGK-neo cassette inserted into intron 24 were introduced to the gene via homologous recombination. This deletion mimics the ApoB-38.9 truncation mutation found in human familial hypobetalipoproteinemia (FHBL). The neo cassette was removed by transient expression of Cre recombinase in correctly targeted ES cells. Southern blot analysis confirmed the absence of the neo cassette in homozygous mutant mice; Western blot analysis showed a mutant proteinproduct of similar size to the human ApoB-38.9 mutant protein. [MGI Ref ID J:65191] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Apobtm1.1Zc, PYRO, vers. 1
Helpful Links
Optimizing PCR Protocols
References
References
Selected Reference(s)
Chen Z; Fitzgerald RL; Averna MR; Schonfeld G. 2000. A targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglycerides J Biol Chem 275(42):32807-15. [PubMed: 10893242] [MGI Ref ID J:65191]
Additional References
Apobtm1.1Zc relatedChen Z; Fitzgerald RL; Li G; Davidson NO; Schonfeld G. 2004. Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele. J Lipid Res 45(1):155-63. [PubMed: 13130124] [MGI Ref ID J:87974]
Chen Z; Fitzgerald RL; Saffitz JE; Semenkovich CF; Schonfeld G. 2003. Amino terminal 38.9% of apolipoprotein B-100 is sufficient to support cholesterol-rich lipoprotein production and atherosclerosis. Arterioscler Thromb Vasc Biol 23(4):668-74. [PubMed: 12615667] [MGI Ref ID J:103058]
Chen Z; Fitzgerald RL; Schonfeld G. 2002. Hypobetalipoproteinemic Mice with a Targeted Apolipoprotein (Apo) B-27.6-specifying Mutation. IN VIVO EVIDENCE FOR AN IMPORTANT ROLE OF AMINO ACIDS 1254-1744 OF ApoB IN LIPID TRANSPORT AND METABOLISM OF THE ApoB-CONTAINING LIPOPROTEIN. J Biol Chem 277(16):14135-45. [PubMed: 11839763] [MGI Ref ID J:76047]
Lin X; Chen Z; Yue P; Averna MR; Ostlund RE Jr; Watson MA; Schonfeld G. 2006. A targeted apoB38.9 mutation in mice is associated with reduced hepatic cholesterol synthesis and enhanced lipid peroxidation. Am J Physiol Gastrointest Liver Physiol 290(6):G1170-6. [PubMed: 16455790] [MGI Ref ID J:111086]
Lin X; Yue P; Xie Y; Davidson NO; Sakata N; Ostlund RE Jr; Chen Z; Schonfeld G. 2005. Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation. Am J Physiol Gastrointest Liver Physiol 289(1):G146-52. [PubMed: 15790761] [MGI Ref ID J:104784]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number AX12
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, heterozygotes are bred to wildtype siblings or to C57BL/6J inbred mice (see Stock No. 000664). The donating investigator reports that homozygous mice are produced in reduced rates and are probably infertile. Mating System +/+ sibling x Heterozygote (Female x Male) Diet Information LabDiet® 5K52/5K67
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price* Gender Genotypes Provided Individual Mouse Price $236.40 Female or Male Heterozygous for Apobtm1.1Zc *Price(s) in US dollars ($)
Pairs /Price* Pair Genotype $288.65 Heterozygous for Apobtm1.1Zc x Wild-type for Apobtm1.1Zc $288.65 Wild-type for Apobtm1.1Zc x Heterozygous for Apobtm1.1Zc
Additional Supply Details
| Supply Notes |
|
|---|
| Pricing for International shipping destinations |
|
Weeks of Age Price* Gender Genotypes Provided Individual Mouse Price $307.40 Female or Male Heterozygous for Apobtm1.1Zc *Price(s) in US dollars ($)
Pairs /Price* Pair Genotype $375.30 Heterozygous for Apobtm1.1Zc x Wild-type for Apobtm1.1Zc $375.30 Wild-type for Apobtm1.1Zc x Heterozygous for Apobtm1.1Zc
Additional Supply Details
| Supply Notes |
|
|---|
|
|
|
Supply Details
| Standard Supply | Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of ~nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within 48 hours of order placement. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
General Terms and Conditions
See Terms of Use
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Effective September 26, 2007: License Requirements for Strains using Cre-lox Technology only apply in Canada, see Licenses for Strains using Cre-lox Technology.
For additional Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice & Services Conditions of Use
“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
No Liability
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.